Bill & Melinda Gates Medical Research Institute

The article discusses the shift in clinical research from inclusive to extractive, influenced by outsourcing to CROs and centralization of decision-making, leading to challenges in patient recruitment and site support. It suggests solutions like increased site support, forming strong country teams, engaging investigators in management practices, and improving payment processes to make clinical research more inclusive and effective.

Clinical trial success in LMICs requires early site visits, active listening, backup strategies, risk identification, and geospatial insights. These practices ensure smooth operations and community engagement.

Dr. Claire Wagner, head of corporate strategy and market access at the Bill & Melinda Gates Medical Research Institute, focuses on developing medications for diseases primarily impacting Low and Middle-Income Countries (LMICs), where commercial incentives are limited. The Gates MRI prioritizes global health equity, targeting diseases like tuberculosis, malaria, and diarrheal diseases. Wagner emphasizes the importance of policy alignment, innovative financing, and strong partnerships to ensure products reach those in need, drawing on her experience in Rwanda and collaborations with global health organizations. The institute is currently developing vaccines and therapeutics, including a TB vaccine candidate and a probiotic supplement for malnourished children.